Ecallantide for the treatment of hereditary angiodema in adults

Clinical Medicine Insights: Cardiology

Volumn 5, Issue , 2011, Pages 49-54

  Lunn, Michael ^a   Banta, Erin ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Acute; Angioedema; Ecallantide; Hereditary angioedema; Kalbitor

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; PLACEBO;

ANGIONEUROTIC EDEMA; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EDEMA; FATIGUE; FEVER; HEADACHE; HOT FLUSH; HUMAN; HYPOTENSION; INJECTION SITE REACTION; NAUSEA; PHARYNGITIS; PRURITUS; RASH; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SNEEZING; THORAX PAIN; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WHEEZING;

EID: 79958024977     PISSN: 11795468     EISSN: 11795468     Source Type: Journal    
DOI: 10.4137/CMC.S4434     Document Type: Review

References (30)

1. Bock SC, Skriver K, Nielsen E, Thoegersen HC, Wiman B, Donaldson VH, et al. Human C1 inhibitor: primary structure, c DNA, cloning, and chromosomal localization. Biochemistry. 1986;25:4292-301.
2. Theriault A, Whaley K, McPhaden AR, Boyd E, Connor JM. Regional assignment of the human C1-inhibitor gene to 11q11-11q13.1. Human Genet. 1990;84:477-9.
3. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor C1-esterase. Am J Med. 1963;35: 37-44.
4. Zuraw BL, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol. 2000;105:541-6.
5. Bowen B, Hawk JJ, Sibunka S, Hovick S, Weiler JM. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations. Clin Immunology. 2001;98: 157-63.
6. Bork K, Barnstedt S, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet. 2000;356:213-7.
7. Binkley K, Davis A. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol. 2000;106:546-50.
8. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest. 1982;69:462-8.
9. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595-628.
10. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. 1997;89:3213-8.
11. Arlaud GJ, Rossi V, Thielens NM, Gaboriaud C, Bersch B, Hernandez JF. Structural and functional studies on C1r and C1s: new insights into the mechanisms involved in C1 activity and assembly. Immunobiology. 1998; 199:303-16.
12. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-7.
13. Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997;90:3819-43.
14. Davis AE III. Mechanism of angioedema in first complement component inhibitor deficiency. Immunol Allergy Clin North Am. 2006;26:633-51.
15. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161:2417-29.
16. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:586-93.
17. Pappalardo E, Cicardi M, Duponchel C, et al. Frequent de novo mutations and exon deletions in the C1 inhibitor gene of patients with angioedema. J Allergy Clin Immunol. 2000;106:1147-54.
18. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119: 267-74.
19. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of longterm stanozolol therapy. J Allergy Clin Immunol. 2007;120:654-8.
20. Rosen FS, Austen KF. The neurotic edema. N Engl J Med. 280(1979): 1356-7.
21. Donaldson VH. Therapy of the neurotic edema. N Engl J Med. 286(1972):835.
22. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Disc. 2010;9: 189-90.
23. Ley AC, Markland W, Ladner RC. Obtaining a family of high-affinity, high specificity protein inhibitors of plasmin and plasma kallikrein. Mol Divers. 1996;2:119-24.
24. Markland W, Ley AC, Ladner RC. Iterative optimization of high-affinity protease inhibitors using phage display. 2. Plasma kallikrein and thrombin. Biochemistry. 1996;35:8058-67.
25. Levy JH, O'Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs. 2006;15: 1077-90.
26. Kalbitor prescribing information. Accessed 1/20/11 http://www.kalbitor.com/hcp/rems/pdf/KalbitorFullPrescribingInformation.pdf.
27. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007; 120:416-22.
28. Levy R, McNeil D, Li H, Hsu FI, Horn P, Roberts J. J Allergy Clin Immunol. February 2008;121(2 Suppl 1):S221.
29. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. Ann Allergy Asthma Immunol. 2010;104:523-9.
30. Epstein TG, Bernstein JA. Current and emerging management options for hereditary angioedema in the US. Drugs. 2008;68:2561-73.